Anti-MAG Antibodies
Anti-MAG antibodies are used to detect the presence of antibodies against myelin-associated glycoprotein (MAG) in the blood, which is often associated with certain types of peripheral neuropathies.
Anti-MAG antibodies help diagnose neuropathy related to MAG autoimmunity.
Key facts at a glance
- Units
- Bühlmann ratio
- Clinical utility
- diagnostic
- Result kind
- qualitative
- FDA-cleared
- Roche Anti-MAG, Siemens Anti-MAG, Buhlmann Anti-MAG
Anti-MAG antibodies are a specific type of autoantibody that target myelin-associated glycoprotein (MAG), a protein crucial for maintaining the integrity of the myelin sheath in the peripheral nervous system.
Elevated levels of anti-MAG antibodies in the blood are indicative of an autoimmune response that can lead to demyelination and subsequent neurological symptoms, such as sensory loss and muscle weakness.
The Bühlmann ratio is a standardized measure used to quantify the levels of anti-MAG antibodies, with a reference range of 0–1 indicating normal levels and higher values suggesting potential neuropathy.
Frequently asked questions
What conditions are associated with elevated anti-MAG antibodies?
How is the anti-MAG antibody test performed?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy